More and More studies indicated that mutations or aberrant upregulation of EZH2 occur frequently in human cancers, However, clinical benefits of EZH2 inhibitor remain unsatisfactory38, this might because that EZH2 is involved in many different signaling pathways and regulated by many different molecules in different tumor types. This evidence concerns the gene EZH2 and cancer.